16th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals
24th — 26th February 2025
Lisbon, Portugal
We look forward to seeing you in Lisbon for another great conference.
Registration prices
Members |
Non members |
Academics |
||
Symposium & Workshop |
900€ |
1,200€ |
900€ |
|
Conference only |
700€ |
1,100€ |
700€ |
|
Workshop only |
390€ |
390€ |
390€ |
- All prices include 23% VAT.
- The EIP Board invites you to be our guest at the social event. If you wish to attend, please ensure that you select this option when booking. Upon confirmation of attendance to the social event, please note that in case of no show a fee of 100.00€ will be charged to cover the costs incurred by EIP.
Sponsoring opportunities
Our annual symposium is the perfect place for your organisation to promote your products and services to an audience of scientific experts active in the area of immunogenicity. The sponsor package includes:
- a booth at the conference hotel
- a free page in the brochure containing the conference agenda
- your logo on the sponsor page of the program
- your logo on the conference page of the EIP website
- free entrance to the meeting for 2 delegates from your company
- full access to the conference including the scientific presentations
- two free invitations to the social event
Package prices:
- for members of the European Immunogenicity Platform: 10,000 €
- for non-members of the European Immunogenicity Platform: 14,000 €
Please email Barbara Vercruyssen if you wish to sponsor the event
After registering as a sponsor, you will receive an invoice. Upon settlement of this invoice, the sponsoring is accepted.
The next step is then to provide us with:
- Your company details and contact person’s name, phone number and email address
- A visual (photo/image/logo) from your organisation
- The URL of your website
- An optional YouTube embed URL
Deadline submission material: December 1, 2025
Deadline booth material at Altis Grand Hotel: February 1, 2025
Material needs to be shipped to:
EIP - Altis Grand Hotel, Rua Barata Salgueiro 50, 1250-096 Lisboa, Portugal
For the attention of: Claudia
Conference: EIP, 24th—26th February 2025 (contact: Barbara Vercruyssen)
Program
Download the program as a PDFNOTE: Preliminary program published 27/11/2024, potentially subject to change. | ||||
Monday, February 24 th 2025 |
||||
Workshop Day | ||||
09:00 | Coming Together | |||
09:15 |
Challenging the current paradigms for clinical immunogenicity testing – the pros and cons Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Christopher Tiedje, BioAgilytix Lydia Michaut, Novartis |
|||
10:15 | Coffee Break | |||
10:45 | Continue “Challenging the current paradigms for clinical immunogenicity testing the pros and cons” | |||
12:15 | Lunch | |||
13:30 |
Bring Your own Problems (Break out Sessions) Daniel Kramer, Sanofi Arno Kromminga, BioNTech Sebastian Spindeldreher, Integrated Biologix Sofie Pattijn, IQVIA Noel Smith, Lonza Sophie Tourdot, Pfizer Tim Hickling, Roche ydia Michaut, Novartis |
|||
15:00 | Coffee Break | |||
15:30 | Continue “Bring Your own Problems (Break out Sessions)” | |||
16:30 | Closing of the Workshop Day | |||
17:00 | 18:30 |
Meeting of the EIP Working Groups Members of EIP working groups |
||
Tuesday, February 25th 2025 |
||||
09:00 |
Welcome and Introduction by the EIP Chairman Daniel Kramer, Sanofi |
|||
09:15 |
Spotlight Presentations: Topic to be confimred Speaker to be confirmed |
|||
Session 2: Prediction of Immunogenicity Chair: Sebastian Spindeldreher |
||||
10:15 |
EIP NCIRA Working Group Update Sebastian Spindeldreher, Integrated Biologix on behalf of EIP |
|||
10:30 |
Analyzing and decreasing the immunogenicity potential of biotherapeutics using in silico approaches Michael Gutknecht, Novartis - invited |
|||
11:00 | Coffee Break | |||
11:30 |
Enhancing Large Molecule Design by Early Integration of MAPPs using Defined Allele Antigen Presenting Cells Andreas Hollenstein, Roche |
|||
12:00 |
The localization of T-cell epitopes in biopharmaceuticals: from peptides to gene therapy vectors Bernard Maillere, University Paris-Saclay |
|||
12:30 | Lunch Break | |||
13:30 |
Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity Michel Siegel, Roche |
|||
14:00 |
Aggregation of therapeutic antibodies enhances dendritic cell uptake and T-cell responses Marc Pallardy, INSERM |
|||
14:30 |
Suitable peptide controls for screening generic peptide products in adaptive immunogenicity assays Chloë Ackaert, IQVIA - invited |
|||
15:00 | Coffee Break | |||
Session 3: Immunogenicity Assays Chair: Arno Kromminga |
||||
15:30 |
EIP Immunogenicity Assays Working Group Update Linlin Luo, Merck Sharp & Dome on behalf of EIP |
|||
15:45 |
Current industry practices for in-study cut point setting for clinical immunogenicity assays Riejanne Bax-Seigers, Icon |
|||
16:15 |
Comparing Signal-to-Noise with titer results – a retrospective analysis Karin Benstein, Sanofi |
|||
16:45 |
Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the clinical support of a bispecific therapeutic antibody Saskia van der Lee, Genmab |
|||
Session 3: Social Event Chair: Barbara Vercruyssen |
||||
18:00 | Get Together | |||
23:00 | Good Night | |||
Wedneday, February 26th 2024 |
||||
Session 4: Immunogenicity Assays continued Chair: Arno Kromminga |
||||
09:00 |
Fit-for-purpose non-clinical immunogenicity assessment to support PK data interpretation – a case study Christopher Tiedje, BioAgilytix |
|||
09:30 |
Evaluating and Mitigating Pre-existing Anti-Drug Antibodies of Bi-Specific Therapeutic Proteins in Early Drug Discovery: A Roche Case Study Janine Faigle, Roche |
|||
Short Talks (15 min) | ||||
10:00 |
A retrospective analysis of clinical immunogenicity data – time for singlicate change Sandra Ribes Miravet, Sandoz Deutschland/Hexal AG - invited |
|||
10:15 |
Is ADA-tiered approach suitable to therapeutics with pre-existing antibodies? Issa Jyamubandi, Intertek |
|||
10:30 | Coffee Break | |||
11:00 |
Generation of anti-drug antibody (ADA) positive control and development of a bridging immunogenicity assay for RNA therapeutics in human serum Oli Gnana Rajaraman, AiCuris Anti-infective Cures AG |
|||
11:15 |
Application of SPR technology for assessment of immunogenicity of a dual-peptide cancer vaccine Daniel Worms, BioAgilytix |
|||
11:30 |
In-depth characterization and semi-quantification of ADAs using innovative hybrid LC-MS methods to support clinical development of biotherapeutics Stephane Muccio, Sanofi |
|||
Session 5: Clinical Relevance of Immunogenicity Chair: Lydia Michaut |
||||
11:45 |
Analysis of Clinical Immunogenicity Data for a Multi-Study Program Susan Irvin, Regeneron |
|||
12:15 |
The effects of the immune modulator methotrexate on anti-drug antibody formation Karin Bloem, Sanquin |
|||
12:45 | Lunch Break | |||
13:45 |
An American Association of Pharmaceutical Scientists (AAPS) Perspective on Clinical Relevance of Immunogenicity Mohsen Rajabi, Novartis (on behalf of AAPS) |
|||
Session 5: Immunogenicity of Novel Modalities Chair: Noel Smith |
||||
14:15 |
The successes in treatment of cancer patients with immunotherapies including T-cell chimeric antigen receptor T-cells (CAR-T) Amy Rosenberg, Epivax |
|||
14:45 |
Exploring alternatives to the 3-tiered immunogenicity testing paradigm for gene therapy programs Robert Nelson, BioAgilytix |
|||
Session 6: Regulatory Chair: Daniel Kramer |
||||
15:15 |
Applying Innate immune response modulating impurities testing for immunogenicity risk assessments: Statistical and regulatory considerations Daniela Verthelyi, FDA |
|||
15:45 |
Topic to be confirmed Speaker to be confirmed |
|||
16:15 |
Conference Summary & Outlook by the EIP Chairman Daniel Kramer, Sanofi |
|||
16:30 | Close of the conference |
Hotel accommodation
Altis Grand Hotel
The conference venue. Special rates have been negotiated for conference attendees. Please book via the special EIP link for these rates to be applied.
Rua Castilho 11
1269-072 Lisboa
Portugal
Ibis Lisboa Centro Liberdade
Just next door to the conference venue, a 2 minute walk.
Rua Barata Salgueiro 53
1250-043 Lisboa
Portugal
Avani Avenida Liberdade Lisbon
A 10 minute walk to the conference venue.
Rua Júlio César Machado 7/9
1250-135 Lisboa
Portugal
Ibis Styles Lisboa Centro Marquês de Pombal
A 15 minute walk to the conference venue.
Av. Fontes Pereira de Melo 5
1069-114 Lisboa
Portugal
Sponsors
We are very happy to have the support of our sponsors for this year’s Symposium.
BioAgilytix
BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany.
For more information, please visit the BioAgilytix website
Celerion
Celerion, a leading early clinical research organization, is equipped with the expertise and resources to surpass your bioanalytical needs, offering services from method development and validation to efficient sample analysis for studies spanning late discovery, preclinical, and late-stage clinical development. With more than 40 years of experience, our laboratories in Zürich, Switzerland, and Lincoln, Nebraska, USA, leverage cutting-edge technology and scientific expertise to accelerate drug development by swiftly providing high-quality data for thorough immunogenicity assessments, pharmacokinetics, and biomarker analysis.
For more information, please visit the Celerion website
SVAR
Svar Life Science is a Swedish group of companies that invents, develops, and applies the best assay technology for drug development and clinical diagnostics with the goal of delivering new solutions tailored to customer requirements. They offer advanced technology platforms such as Functional Complement Biomarker and Screening assays and Cell-based Reporter Gene assays, as well as unique service models for Bioassays Customization, Custom Cell line Development in combination with GxP Laboratory Services, all designed to meet their customers’ specific project needs.
For more information, please visit the SVAR website